Sign In
Buy LTRN
$3.40
-0.340 (-9.09%)
At Close: Jun 03, 2026
Lantern Pharma Inc. (LTRN) Shareholder/Analyst Call Transcript
01:01pm, Thursday, 09'th Apr 2026
Lantern Pharma Inc. (LTRN) Shareholder/Analyst Call Transcript
DALLAS--(BUSINESS WIRE)--withZeta.ai is redefining how rare cancer research, discovery, drug development, and clinical trial design gets done.
Lantern Pharma Inc. (LTRN) Q4 2025 Earnings Call Prepared Remarks Transcript
07:52pm, Monday, 30'th Mar 2026
Lantern Pharma Inc. (LTRN) Q4 2025 Earnings Call Prepared Remarks Transcript
Lantern Pharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
04:05pm, Monday, 30'th Mar 2026
DALLAS--(BUSINESS WIRE)--Lantern Pharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates.
Lantern Pharma Confirms Panna Sharma Continues to Serve as President and CEO; Alerts Investors to False Third-Party Report
07:23pm, Friday, 27'th Mar 2026
DALLAS--(BUSINESS WIRE)--Lantern Pharma Confirms Panna Sharma Continues to Serve as President and CEO; Alerts Investors to False Third-Party Report.
DALLAS--(BUSINESS WIRE)--Lantern Pharma and Starlight Therapeutics Announce FDA Clearance of IND for a Planned Phase 1 Pediatric CNS Cancer Trial of STAR-001.
Lantern Pharma to Report Fourth Quarter and Fiscal Year 2025 Operating & Financial Results on March 30th, 2026 at 4:30 p.m. ET
04:30pm, Monday, 23'rd Mar 2026
DALLAS--(BUSINESS WIRE)--Lantern Pharma to Report Fourth Quarter and Fiscal Year 2025 Operating & Financial Results on March 30th, 2026 at 4:30 p.m. ET.
Lantern Pharma to Present at the 7th Glioblastoma Drug Development Summit in Boston on February 17-19, 2026
08:45am, Tuesday, 10'th Feb 2026
DALLAS--(BUSINESS WIRE)--Lantern Pharma to Present at the 7th Glioblastoma Drug Development Summit in Boston on February 17-19, 2026.
Lantern Pharma's LP-284 Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas
08:00am, Tuesday, 20'th Jan 2026
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using artificial intelligence to transform the cost, pace, and timeline of oncology drug discove
DALLAS--(BUSINESS WIRE)--A.I. center of excellence - Lantern Pharma.
DALLAS--(BUSINESS WIRE)--LP-184 Clinical Insights, KOL Webinar & Future Plans.
2 sub‑$10 AI stocks to outperform Palantir in 2026, according to ChatGPT‑5
02:58pm, Sunday, 23'rd Nov 2025
Palantir Technologies (NASDAQ: PLTR) has grown into a dominant force in AI-driven data analytics, securing lucrative government contracts and expanding its mission-critical intelligence business.
Lantern Pharma Inc. (LTRN) Discusses LP-184 Phase 1a Clinical Results and Implications for DNA Damage Repair-Deficient Tumors Transcript
08:33pm, Thursday, 20'th Nov 2025
Lantern Pharma Inc. ( LTRN ) Discusses LP-184 Phase 1a Clinical Results and Implications for DNA Damage Repair-Deficient Tumors November 20, 2025 4:30 PM EST Company Participants Panna Sharma - Presid
Lantern Pharma Inc. (LTRN) Q3 2025 Earnings Call Transcript
01:11pm, Thursday, 13'th Nov 2025
Lantern Pharma Inc. ( LTRN ) Q3 2025 Earnings Call November 13, 2025 9:00 AM EST Company Participants Panna Sharma - President, CEO & Director David Margrave - CFO & Secretary Presentation Operator Go
Lantern Pharma Reports Third Quarter 2025 Financial Results and Provides Business Updates
08:30am, Thursday, 13'th Nov 2025
DALLAS--(BUSINESS WIRE)--Q3 Press Release - BTM.
